GOLDSTEIN DOV A MD bought BIOA
January 13, 2026 · Form 4 insider transaction
GOLDSTEIN DOV A MD bought 27,000 shares of BioAge Labs, Inc. at $8.39 per share, a transaction worth $226.5K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
27,000
Price
$8.39
Total value
$226.5K
InsiderGOLDSTEIN DOV A MD
RoleOfficer, Director
CompanyBioAge Labs, Inc. (BIOA)
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateJanuary 13, 2026
Filing dateJanuary 15, 2026
Shares owned after49,408
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024.